Proyectos

Código

220365

Investigador/a principal

Begoña Nafria Escalera

Rol

Coordinador

Año de inicio

2022

Año de finalización

2024

Import total

334990,39€

Objectius

EIT HEALTH_Begonya Nafria

Código

220628

Investigador/a principal

Josep Maria Haro Abad

Rol

Participant

Año de inicio

2022

Año de finalización

2024

Import total

224717,97€

Objectius

EIT HEALTH_Dr. Josep Maria Haro

Código

SLT017/20/000228

Investigador/a principal

Lourdes Ibañez Toda

Rol

Individual

Año de inicio

2021

Año de finalización

2024

Import total

91124,31€

Objectius

DEPARTAMENT DE SALUT_Dra. Lourdes Ibañez

Código

SLT017/20/000199

Investigador/a principal

MªAngels García Cazorla

Rol

Individual

Año de inicio

2021

Año de finalización

2024

Import total

91095,68€

Objectius

DEPARTAMENT DE SALUT_Àngels García Cazorla

Código

965226

Investigador/a principal

Maria Rubio Valera

Rol

Participant

Año de inicio

2021

Año de finalización

2026

Import total

167728,75€

Objectius

Healthcare fragmentation is a main cause for delay in cancer diagnosis and treatment, contributing to high and steadily increasing mortality rates in Latin America(LA), particularly among disadvantaged populations. Building on Equity-LA I (GA223123) and II (GA305197), this research focuses on integrated care interventions, which have proven effective at improving early diagnosis of cancer, mostly in HIC, and are also promoted by national cancer plans in LA, but limitedly implemented or evaluated. The objective is to evaluate the contextual effectiveness of scaling-up a multicomponent integrated care intervention to improve early diagnosis of frequent cancers in healthcare networks of Chile, Colombia and Ecuador. Method: This participatory, interdisciplinary and mix-methods implementation research is two-pronged: a) a quasiexperimental design (controlled before and after) with an intervention and a control healthcare network; b) a case study design. Focussing on the most vulnerable socioeconomic population, it develops in four phases: 1) analysis of delays, related factors and contextual barriers to early diagnosis (base-line); 2) adaptation and scaling-up of the intervention (PC
training, fast-track referral pathway and patient information, adapting available ICT tools) in real life; 3) intra-country evaluation of intervention; 4) cross-country analysis. ICT tools will be also adopted in research activities as needed in a Covid-19 on-going or post- pandemic context. Relevance: EquityCancer-LA contributes to H2020 call objectives advancing cancer control policies by generating: 1) robust evidence on contextual effectiveness and costs-effectiveness of an affordable, tailored intervention to reduce diagnostic delays; and a validated strategy for its large-scale implementation in LA and LMICs; 2) novel data on delays and key barriers and facilitators to early diagnosis and inequalities in access; 3) e-tools to improve clinical practice and research on early diagnosis.

Código

899671

Investigador/a principal

Lourdes Ibañez Toda

Rol

Coordinador

Año de inicio

2021

Año de finalización

2026

Import total

1720031,25€

Objectius

Polycystic Ovary Syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5-10% of AYAs worldwide. It is the most frequent cause of anovulatory subfertility. There is no approved therapy for PCOS. Standard off-label treatment with oral contraceptives reverts neither the underlying
pathophysiology nor the associated co-morbidities
Pilot studies have generated new insights into the pathophysiology of PCOS, and have thus led to the development of a new approach wherein the PCOS phenotype is reverted without side effects. The novel medication is a fixed, low-dose combination of two insulin sensitisers [Pioglitazone (Pio), Metformin (Met)] and one mixed anti-androgen and antimineralocorticoid (Spironolactone (Spi)] within a single tablet: SPIOMET
SPIOMET4HEALTH will test, in a multicentre Phase II trial, the additive effects of each SPIOMET component, on top of lifestyle measures in AYAs with PCOS. SPIOMET aims at normalising the ovulation rate and endocrine-metabolic status via the reduction of hepato-visceral fat excess, in an early phase of the disorder. This approach is expected to reduce the risk of morbidity (including subsequent anovulatory subfertility), to improve the quality of life, and to lower the economic burden on European healthcare systems.
The consortium clusters the experts from key research groups working on PCOS in AYAs, across Europe. The design of SPIOMET4HEALTH foresees that the patients themselves will be engaged over the entire timespan of the project, and will also contribute to the ultimate study evaluation. The update and validation of PCOS-specific Patient Reported Outcome Measures (PROM) will provide the first large-scale evidence on the psychosocial benefits of the tested treatments.
The collective evidence from SPIOMET4HEALTH, once completed with economic modelling, will lead to conclusions that inform sound decision-making about PCOS across European healthcare systems.

Código

948973

Investigador/a principal

Maria Rubio Valera

Rol

Individual

Año de inicio

2021

Año de finalización

2026

Import total

1231075€

Objectius

Between 3 and 42% of patients do not initiate their treatments. Non-initiation and non-adherence are associated with poorerclinical outcomes, more days of sick leave and higher costs.The aim of this research project is to generate an effective, efficient and feasible intervention that improve initiation and
adherence and improves clinical symptoms. The long-term benefits in terms of improved health and reduced costs will beevaluated. The results will be disseminated to stakeholders, decision-makers and the scientific community to promote
implementation. The intervention is expected to improve the clinical practice, empowering the patient. The project developsan innovative approach to the design and evaluation of behavioural interventions that uses the principles of complex
interventions, pragmatic trials and implementation research.
Nine interventions to reduce non-initiation have been tested. The interventions were not theory-based and most used simplereminders. The evidence supporting these interventions was low and their impact on clinical symptoms and costeffectiveness
was not assessed. The strengths of the IMA-cRCT study are: 1) the main stakeholders are involved in thedesign and assessment; 2) IMA intervention is theory-based and has been optimized; 3) the study will assess the impact of
the intervention on clinical parameters and cost-effectiveness, which is key to guarantee its transferability; 4) the projectinvolves decision-makers; 5) the pragmatic design increases generalisation and 6) the intervention is easily transferable toother pathologies, populations and countries.As part of the ERC research project, a pragmatic cluster randomized controlled trial (cRCT) will evaluate the short-termeffects of the IMA intervention and its cost-effectiveness and Markov models will be constructed to estimate its long-termcost-effectiveness. The results will be disseminated to facilitate its transferability to clinical practice in Spain and Europe.

Código

ICI20/00080

Investigador/a principal

Juan Vicente Luciano Devis

Rol

Individual

Año de inicio

2021

Año de finalización

2024

Import total

270811,2€

Objectius

Objetivos: Evaluar la efectividad y la seguridad de la naltrexona a dosis bajas (LDN) en pacientes con fibromialgia (FM) y comparar su coste-utilidad desde las perspectivas sanitaria y del gobierno a los 12 meses de seguimiento. Se incluirán metabolitos cerebrales y biomarcadores inflamatorios sistémicos para evaluar los mecanismos neurobiológicos que subyacen a los efectos terapéuticos de la LDN.
Diseño: Ensayo clínico controlado, aleatorizado, doble ciego.
Centro: Parc Sanitari Sant Joan de Déu (Sant Boi de Llobregat).
Participantes: 120 pacientes con FM que cumplan con los criterios de elegibilidad del estudio se asignarán al azar a LDN (4,5 mg de naltrexona/día durante 12 meses, como tratamiento complementario) o a placebo.
Medida principal del estudio: severidad del dolor mediante la Evaluación Ecológica Momentánea (EMA) con la app Pain Monitor©. Medidas secundarias: otros síntomas nucleares de la FM, funcionalidad, sintomatología afectiva, fibrofog y calidad de vida. Se calcularán los costes (tanto desde la perspectiva gubernamental como la de salud) y los años de vida ajustados por calidad (AVACs). Biomarcadores: el 50% de la muestra será escaneada a nivel basal y a las 12 semanas en busca de cambios en los metabolitos cerebrales relacionados con la neuroinflamación y la sensibilización central (i.e. glutamato) en las siguientes áreas cerebrales: ínsula posterior, corteza cingulada posterior y anterior y corteza prefrontal ventrolateral; También se obtendrán marcadores inflamatorios en suero: IL-1", sIL-1ra, IL-6, sIL-6r, sgp130, IL-8, TNF-a, IL-10 y proteína C reactiva de alta sensibilidad.
En definitiva, este es un estudio de reposicionamiento terapéutico en el que pretendemos demostrar que un medicamento muy económico (LDN) puede ser efectivo, seguro y coste-útil en el manejo de un síndrome altamente prevalente y discapacitante como es la fibromialgia.

Código

101017113

Investigador/a principal

Marta Camprubi Camprubi, Joan Sánchez de Toledo

Rol

Participant

Año de inicio

2021

Año de finalización

2024

Import total

563750€

Objectius

The brain of the newborn is very different from the adult posing a major problem in assessing the origins of its injuries and in developing therapeutics. This is further complicated when the newborn was born prematurely or its in-utero development has
been compromised. In these situations, their interplay between contributing factors become complex to understand with current tools since they are technically and ethically difficult to employ widely. TinyBrains will develop a neuro-imager and
focus on congenital heart-defects (CHD). CHD is the most prevalent congenital malformation with about a million births worldwide annually. Advances in surgical techniques and perioperative management have dramatically reduced mortality
rates with more than 85% surviving to adulthood. However, significant neurodevelopmental problems are observed in about 50% due to brain injury. It being so prevalent and also having accepted accionable points in its care and therapy, TinyBrains
chose CHD as its target to provide a research platform to improve the understanding of the cellular origin of the brain injury by enabling the assessment of the link between energy demand and oxygen supply. To so, we will combine advanced
biophotonics technologies and electroencephalography into a disruptive research tool enabling research into new brainoriented therapies and management strategies. TinyBrains will measure cerebral hemodynamics, oxygen metabolism and
electrophysiology simultaneously. In vivo imaging in three-dimensions, i.e. tomography, will greatly increase the brain specificity and penetration as well as, for the first time, providing spatial resolution to this class of measurements.
This plethora of information will enable us to carry out pre-clinical animal and clinical studies in infants with and without CHD to gain a peek at the cellular origins of brain injury. By bringing together academia, clinics and industry, TinyBrains further
seeks to create the path for exploitation.

Código

FI20/00034

Investigador/a principal

Juan Vicente Luciano Devis

Rol

Individual

Año de inicio

2021

Año de finalización

2024

Import total

82400€

Objectius

ISCIII_Dr. Juan Vicente Luciano